gemfibrozil has been researched along with Heart Disease, Ischemic in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gemfibrozil-statin combination therapy is a well-known risk factor for myopathy and rhabdomyolysis." | 7.70 | A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report. ( Boran, M; Gökçe, V; Koçak, B; Korkmaz, S; Ozdemir, O; Uzun, Y, 2000) |
| " The three groups were similar for age, sex and geographical region, but significantly more patients on bezafibrate had diabetes and/or hypertension than those on gemfibrozil or simvastatin." | 3.70 | A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP). ( Beggs, PW; Clark, DW; Coulter, DM; Williams, SM, 1999) |
| "Gemfibrozil-statin combination therapy is a well-known risk factor for myopathy and rhabdomyolysis." | 3.70 | A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report. ( Boran, M; Gökçe, V; Koçak, B; Korkmaz, S; Ozdemir, O; Uzun, Y, 2000) |
| "A decision to treat hyperlipidemias would be based on the assumption that such disorders lead to accelerated atherogenesis and ultimately to cardiac dysfunction." | 1.30 | Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation. ( Kesten, S; Maurer, J; Mayne, L; Scavuzzo, M, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H | 1 |
| Liu, LL | 1 |
| Ye, LL | 1 |
| McGuckin, C | 1 |
| Tamowski, S | 1 |
| Scowen, P | 1 |
| Tian, H | 1 |
| Murray, K | 1 |
| Hatton, WJ | 1 |
| Duan, D | 1 |
| Milionis, HJ | 2 |
| Elisaf, MS | 1 |
| Mikhailidis, DP | 2 |
| Gami, A | 1 |
| Gault, MH | 1 |
| Longerich, LL | 1 |
| Purchase, L | 1 |
| Harnett, J | 1 |
| Breckenridge, C | 1 |
| Kesten, S | 1 |
| Mayne, L | 1 |
| Scavuzzo, M | 1 |
| Maurer, J | 1 |
| Beggs, PW | 1 |
| Clark, DW | 1 |
| Williams, SM | 1 |
| Coulter, DM | 1 |
| Ozdemir, O | 1 |
| Boran, M | 1 |
| Gökçe, V | 1 |
| Uzun, Y | 1 |
| Koçak, B | 1 |
| Korkmaz, S | 1 |
| Rizos, E | 1 |
3 reviews available for gemfibrozil and Heart Disease, Ischemic
| Article | Year |
|---|---|
Treatment of dyslipidaemias in patients with established vascular disease: a revival of the fibrates.
Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Gemfibrozil; Humans; Hydroxymethylg | 2000 |
Secondary prevention of ischaemic cardiac events.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 2006 |
Smoking diminishes the beneficial effect of statins: observations from the landmark trials.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Gemfibrozil; Humans; Lovastatin; Myocardial Isch | 2001 |
5 other studies available for gemfibrozil and Heart Disease, Ischemic
| Article | Year |
|---|---|
Targeted inactivation of cystic fibrosis transmembrane conductance regulator chloride channel gene prevents ischemic preconditioning in isolated mouse heart.
Topics: Animals; Chlorides; Cystic Fibrosis Transmembrane Conductance Regulator; Gemfibrozil; Ion Transport; | 2004 |
Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apolipoprotein B-100; Apolipoproteins A; Apolipoproteins | 1995 |
Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Echocardiography; Fem | 1997 |
A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP).
Topics: Bezafibrate; Cohort Studies; Comorbidity; Diabetes Complications; Female; Gemfibrozil; Humans; Hyper | 1999 |
A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report.
Topics: Diabetes Mellitus; Drug Interactions; Drug Therapy, Combination; Electrocardiography; Fatal Outcome; | 2000 |